Pravastatin: An Antithrombotic Effect Independent of the Cholesterol-lowering Effect

Summary

Lipid-lowering with statins reduces blood thrombogenicity. However, it is unknown whether this is purely due to LDL-cholesterol reduction, or it is related to a statin or agent specific effect. We investigated the relationship between reduction in blood thrombogenicity and the magnitude of low-density lipoprotein cholesterol (LDL-C) during pravastatin therapy.

We prospectively followed for 6 months 57 hyperlipidemic patients who initiated therapy with pravastatin, and 36 patients who were randomized into placebo plus diet. Pravastatin-treated patients were grouped according to the LDL-C reduction at 6 months; (i) “adequate LDL-C reduction”: LDL-C reduction >30% from baseline or LDL-C<125 mg/dl (n = 38; LDL-C reduction 74 ± 4 mg/dl; 6-month LDL-C 119 ± 5 mg/dl); (ii) “inadequate LDL-C reduction”: neither of the above criteria (n = 19; LDL-C reduction 31 ± 5 mg/dl; 6-month LDL-C 158 ± 6 mg/dl). Placebo patients were divided into those “with LDL-C reduction” (n = 17, mean reduction 21 ± 5 mg/dl) and those “without LDL reduction” (n = 19).

The following parameters were altered at 6 months in both patients with “adequate” and “inadequate” LDL-C reduction: (1) tissue plasminogen activator decreased by 1.4 ± 0.4 and 1.5 ± 0.5 ng/ml respectively (p = NS); (2) plasminogen activator inhibitor-1 decreased by 8.7 ± 2.0 and 10.1 ± 2.7 ng/ml respectively (p = NS); (3) thrombus formation under dynamic flow conditions decreased by 3.5 ± 0.9 and 2.8 ± 1.2 µm² × 10³ respectively (p = NS). In contrast, no significant changes from baseline were noted in placebo-treated patients, regardless of their LDL-C reduction category, and multivariate analysis eliminated LDL-C reduction as an independent predictor of reduction in thrombogenicity.

Therefore, the reduction in thrombogenicity was not proportional to the magnitude of LDL-C reduction suggesting that a class or agent specific property is primarily responsible for the pro-fibrinolytic/antithrombotic effects observed.

Keywords

Lipids - platelet - endothelium - thrombus

• References

• 1 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med 1998; 339: 1349-57.
• 2 Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
• 3 Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langerdorfer A, Stein EA, Kruyer W, Gotto AM. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA 1998; 279: 1615-22.
• 4 Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye LA, Rouleau JL, Pfeffer MA, Braunwald E. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32: 140-6.
• 5 Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286-93.
• 6 Kearney D, Fitzgerald D. The anti-thrombotic effects of statins. J Am Coll Cardiol 1999; 33: 1305-7.
• 7 Rosenson RS, Tagney CC. Antiatherothrombotic properties of statins: implications for cardiovascular events reduction. JAMA 1998; 279: 1643-50.
• 8 Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, Meraj P, Fier C, Fallon JT, Ambrose JA. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33 5: 1294-304.
• 9 Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7.
• 10 Rauch U, Badimon JJ, Vorchheimer DA. et al. Lipid lowering therapy reduces blood thrombogenicity in hypercholesterolemic patients: effect of simvastatin. J Am Coll Cardiol 1998; 31 (Suppl A): 194A.
• 11 Tsuda Y, Satoh K, Kitadi M. Effects of prevastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122: 225-33.
• 12 Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet thrombus formation in hypercholesterolemic coronary patients. J Am Coll Cardiol 1996; 27 (Suppl A): 413A.
• 13 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantification of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
• 14 Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: Deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-18.
• 15 Dangas G, Badimon JJ, Coller BS, Fallon JT, Sharma SK, Hayes RM, Meraj P, Ambrose JA, Marmur JD. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition under dynamic flow conditions. Implications for a potential anticoagulant effect of abciximab. Arterioscl Thromb Vasc Biol 1998; 18: 1342-9.
• 16 Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GBJ. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin atherosclerosis Intervention Program. Circulation 1995; 92: 2419-25.
• 17 West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study (WOSCOPS). Circulation 1998; 97: 1440-5.
• 18 Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995; 92: 2333-42.
• 19 Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
• 20 Dangas G, Mehran R, Wallenstein S, Courcoutsakis NA, Kakarala V, Hollywood J, Ambrose JA. Correlation between angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997; 29: 519-25.
• 21 Vanderkerchove Y, Baele G, dePuydt H, Weyne A, Clement D. Plasma tissue plasminogen activator levels in patients with coronary heart disease. Thromb Res 1988; 50: 449-53.
• 22 Ridker PM, Vaughn DE, Stampfer MJ. Baseline fibrinolytic state and the risk of future venous thrombosis: a prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-7.
• 23 Vorchheimer DA, Rauch U, Dandler DA, Fuster V, Chesebro JA, Arslan B, Guzman IC, Palencia S, Badimon JJ. Statin therapy reduces blood thrombogenicity: evidence for an antithrombotic effect independent of LDL reduction. Circulation 1998; 17 (Suppl I): I-452 (Abstract).